Johnson & Johnson secured a priority review from the U.S. Food and Drug Administration for apalutamide to treat men with a form of prostate cancer.
The FDA expects to deliver a decision on the application by April 2018.
Priority review ensures that the FDA takes action upon an application within six months of submission, as compared to the 10-month period for standard reviews.
Apalutamide is an investigational oral androgen receptor inhibitor for treating men with nonmetastatic castration-resistant prostate cancer. There are no FDA-approved treatments for the condition.
The company submitted the application in October.
